Damora Therapeutics, Inc. (GLTO) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Market Cap | 33.64M |
| Enterprise Value | -223.91M |
| P/E Ratio | -0.16 |
| PEG Ratio | 0 |
| Price/Sales Ratio | 0 |
| Price/Book Ratio | 0.07 |
| Enterprise/Revenue | 0 |
| Enterprise/EBITDA | -5.21 |
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | March 31, 2026 |
| Profit Margin | 0 |
| Operating Margin | 0 |
| Return On Assets | -0.44 |
| Return On Equity | -1.23 |
| Revenue | 0 |
| Revenue/Share | 0 |
| Gross Profit | -34,000 |
| EBITDA | -209.76M |
| Net Income | -209.84M |
| Diluted EPS | -3.71 |
| Total Cash | 532.9M |
| Total Cash/Share | 401.57 |
| Total Debt | 1.34M |
| Total Debt/Equity | 0 |
| Current Ratio | 22.48 |
| Book Value Per Share | 384.51 |
| 52-Week Change | 564 |
| 52-Week High | 38.33 |
| 52-Week Low | 2.01 |
| Moving Average 50 Days | 26.12 |
| Moving Average 200 Days | 13.34 |
| Average Volume | 480,389 |
| Shares Outstanding | 1.6M |
| % Held by Institutions | 14.89 |
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | 1:25 |
| Last Split Date | August 30, 2024 |